InflaRx (IFRX) Competitors $1.82 +0.13 (+7.69%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$1.82 -0.01 (-0.27%) As of 05/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. MAZE, SIGA, ZVRA, SAGE, AMLX, PRTA, PRTC, ABVX, TRML, and PGENShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Maze Therapeutics (MAZE), SIGA Technologies (SIGA), Zevra Therapeutics (ZVRA), Sage Therapeutics (SAGE), Amylyx Pharmaceuticals (AMLX), Prothena (PRTA), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), Tourmaline Bio (TRML), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Maze Therapeutics SIGA Technologies Zevra Therapeutics Sage Therapeutics Amylyx Pharmaceuticals Prothena PureTech Health ABIVAX Société Anonyme Tourmaline Bio Precigen Maze Therapeutics (NASDAQ:MAZE) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, community ranking, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Is MAZE or IFRX more profitable? Maze Therapeutics has a net margin of 0.00% compared to InflaRx's net margin of -33,362.70%. Maze Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets Maze TherapeuticsN/A N/A N/A InflaRx -33,362.70%-65.98%-56.86% Do analysts rate MAZE or IFRX? Maze Therapeutics currently has a consensus target price of $25.67, suggesting a potential upside of 152.38%. InflaRx has a consensus target price of $8.50, suggesting a potential upside of 367.03%. Given InflaRx's higher possible upside, analysts plainly believe InflaRx is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40InflaRx 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer MAZE or IFRX? InflaRx received 238 more outperform votes than Maze Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Maze Therapeutics an outperform vote while only 65.24% of users gave InflaRx an outperform vote. CompanyUnderperformOutperformMaze TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesInflaRxOutperform Votes24465.24% Underperform Votes13034.76% Do insiders and institutionals hold more shares of MAZE or IFRX? 42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, MAZE or IFRX? Maze Therapeutics has higher revenue and earnings than InflaRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaze Therapeutics$167.50M2.66N/AN/AN/AInflaRx$129.75K941.66-$46.18M-$0.82-2.22 Does the media prefer MAZE or IFRX? In the previous week, InflaRx had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Maze Therapeutics. InflaRx's average media sentiment score of 0.92 beat Maze Therapeutics' score of 0.73 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryInflaRx beats Maze Therapeutics on 8 of the 15 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$122.18M$6.47B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-1.699.0626.8019.71Price / Sales941.66251.66397.78120.67Price / CashN/A65.8538.2534.62Price / Book0.966.456.774.50Net Income-$46.18M$143.98M$3.23B$248.22M7 Day Performance9.64%0.38%0.48%-0.78%1 Month Performance51.67%2.14%9.13%11.53%1 Year Performance22.97%-0.33%18.58%8.99% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx2.5585 of 5 stars$1.82+7.7%$8.50+367.0%+11.7%$122.18M$129,752.00-1.6960MAZEMaze TherapeuticsN/A$10.13+5.3%$25.67+153.4%N/A$443.65M$167.50M0.00121Gap UpSIGASIGA Technologies1.1547 of 5 stars$5.94+4.9%N/A-21.9%$424.36M$138.72M4.9540ZVRAZevra Therapeutics3.2348 of 5 stars$7.75-1.5%$22.29+187.6%+85.1%$423.76M$23.61M-3.9320Analyst UpgradeSAGESage Therapeutics3.9369 of 5 stars$6.75+2.9%$8.81+30.6%-45.4%$410.79M$47.40M-1.02690AMLXAmylyx Pharmaceuticals3.4374 of 5 stars$4.60-0.2%$9.67+110.1%+192.9%$409.79M$-1,272,000.00-1.20200PRTAProthena3.853 of 5 stars$7.61+2.4%$51.71+579.6%-69.7%$409.62M$137.94M-3.31130High Trading VolumePRTCPureTech Health2.1304 of 5 stars$17.03+1.5%$45.00+164.3%-40.1%$408.92M$4.32M0.00100Positive NewsGap UpABVXABIVAX Société Anonyme2.44 of 5 stars$6.40-4.6%$34.00+431.3%-57.7%$405.88MN/A0.0061TRMLTourmaline Bio1.8449 of 5 stars$15.78+4.5%$49.33+212.6%+12.0%$405.31MN/A-5.6044PGENPrecigen3.3794 of 5 stars$1.37+3.0%$7.00+410.9%+0.7%$404.38M$3.93M-2.49190Gap UpHigh Trading Volume Related Companies and Tools Related Companies Maze Therapeutics Competitors SIGA Technologies Competitors Zevra Therapeutics Competitors Sage Therapeutics Competitors Amylyx Pharmaceuticals Competitors Prothena Competitors PureTech Health Competitors ABIVAX Société Anonyme Competitors Tourmaline Bio Competitors Precigen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
